LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer

Authors: Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric

Source: Future oncology. 18(28):3143-3150

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100191695697.0x000001&indx=1&recIds=ETOCvdc_100191695697.0x000001

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

Authors: Geoerger, Birgit, Morland, Bruce, Jiménez, Irene, Frappaz, Didier, Pearson, Andrew D.J., Vassal, Gilles, Maeda, Patricia, Kincaide, Jasmine, Mueller, Udo, Schlief, Sarah, Teufel, Michael, Ploeger, Bart A., Cleton, Adriaan, Agostinho, Andrea C., Marshall, Lynley V.

Source: In European Journal of Cancer August 2021 153:142-152

Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.

Authors: Regnault, Antoine, Bunod, Laurine, Loubert, Angely, Brose, Marcia S., Hess, Lisa M., Maeda, Patricia, Lin, Yan, Speck, Rebecca M., Gilligan, Adrienne M., Payakachat, Nalin

Source: Journal of Patient-Reported Outcomes; 12/18/2024, Vol. 8 Issue 1, p1-10, 10p

Subject Terms: THERAPEUTIC use of antineoplastic agents, MULTITRAIT multimethod techniques, THYROID gland tumors, PATIENT safety, RESEARCH funding, FUNCTIONAL assessment, PROTEIN-tyrosine kinase inhibitors, RESEARCH methodology evaluation, ANTINEOPLASTIC agents, QUESTIONNAIRES, CANCER cells, PSYCHOMETRICS, INTRACLASS correlation, STATISTICAL reliability, HEALTH outcome assessment

Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.

Authors: Wirth, Lori J., Brose, Marcia S., Subbiah, Vivek, Worden, Francis, Solomon, Ben, Robinson, Bruce, Hadoux, Julien, Tomasini, Pascale, Weiler, Daniela, Deschler-Baier, Barbara, Tan, Daniel S.W., Maeda, Patricia, Lin, Yan, Singh, Ravinder, Bayt, Theresa, Drilon, Alexander, Cassier, Philippe A.

Source: Journal of Clinical Oncology; 9/20/2024, Vol. 42 Issue 27, p3187-3195, 11p

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

Authors: Baselga, José, Zamagni, Claudio, Gómez, Patricia, Bermejo, Begoña, Nagai, Shigenori E., Melichar, Bohuslav, Chan, Arlene, Mángel, Lászlo, Bergh, Jonas, Costa, Frederico, Gómez, Henry L., Gradishar, William J., Hudis, Clifford A., Rapoport, Bernardo L., Roché, Henri, Maeda, Patricia, Huang, Liping, Meinhardt, Gerold, Zhang, Joshua, Schwartzberg, Lee S.

Source: In Clinical Breast Cancer December 2017 17(8):585-594

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve -mutant medullary thyroid cancer.

Authors: Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric

Source: Future Oncology; Sep2022, Vol. 18 Issue 27, p3143-3150, 8p

Innovation in Services: The Case of Fleury–A Diagnostic Medical Center.

Authors: Vasconcellos, Eduardo, Vasconcellos-Guedes, Liliana, Franco, Rendrik, Maeda, Patricia Yumi, Guedes, Luís F. A., Bruno, Marcos C.

Source: Managing Consumer Services; 2014, p211-231, 21p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.